News & Industry Bulletins

Tuesday, October 14, 2014

Leading Medication Monitoring Coalition Announces Election of Robert Garvey to Serve as New Chairman

The Coalition for Excellence in Medication Monitoring (CEMM) – the leading voice of the medication monitoring clinical laboratory industry – has elected Robert Garvey, CEO of Dominion Diagnostics, to serve as its new Chairman.

Tuesday, September 30, 2014

Dominion Diagnostics Now Offers Detection of "Z-Drugs" Commonly Prescribed for Insomnia

Dominion Diagnostics, a leading national provider of drug testing, medication monitoring, and actionable clinical information, now offers a new laboratory‐based urine test for the detection of commonly prescribed Z‐Drugs.

Tuesday, September 23, 2014

Improvement of Abstinence in Chemical Dependence Treatment Programs with Comprehensive Analysis of Reported Drugs (CARD)®

Scientists in the open access journal PLOSONE reported today on a comprehensive systematic evaluation of compliance to prescribed treatment medications and abstinence from psychoactive drug abuse in chemical dependence programs.

Wednesday, August 27, 2014

DEA Bumps Hydrocodone-Combination Products to Schedule II Drugs

The U.S. Drug Enforcement Administration (DEA) has reclassified hydrocodone-combination products as the more restrictive Schedule II drugs in an attempt to curb drug abuse. The DEA published the Final Rule in the Federal Register on Aug. 22. The Final Rule will take effect in 45 days and will apply to “all pharmaceuticals containing hydrocodone currently on the market in the United States.”

Wednesday, August 20, 2014

Methadone Guidelines Focus On Primary Care

New guidelines drafted by the American Pain Society (APS) for the safe administration of methadone for the first time focus particular attention on the potential for abuse and misuse of the drug, highlighting the need for additional awareness and education within the pain management community, after a significant increase in deaths related to its use.

Friday, July 25, 2014

Ten Drugs Cause Majority of ER Visits in Adults for Adverse Psych Med Effects

Nearly 90,000 adults go to emergency rooms each year for side effects of psychiatric medications, and a few specific drugs may be to blame for 57% of those visits, a new study has found.

Thursday, July 17, 2014

Dominion Diagnostics employees donate to Project Sweet Peas, a local RI organizations supporting NICU families

Dominion Diagnostics recently hosted a donation drive to benefit Project Sweet Peas, an organization that provides comfort to families with children in the Women and Infants neonatal intensive care unit (NICU). There are a number of Dominion Diagnostics employees who have been beneficiaries of support services from Project Sweet Peas.

Wednesday, July 2, 2014

Five ways to combat prescription drug abuse

Prescription drug abuse is a serious public health problem that has reached crisis levels across the United States. The governors of five New England states met earlier this week to discuss how to combat prescription drug abuse and diversion. The American Medical Association hopes they will focus on a five-pronged comprehensive, public health approach that emphasizes treatment and prevention. 

Tuesday, April 22, 2014

Chief Scientific Advisor Kenneth Blum, PhD Receives 2014 ASAM Medical-Scientific Program Committee Award for Best Scientific Abstract

Kenneth Blum, PhD, President and CEO of IGENE, LLC, has long been associated with leading drug monitoring laboratory Dominion Diagnostics in a scientific research and advisory role. Blum, who sits on Dominion’s Addiction and Scientific Advisory Board, was recently appointed Chief Scientific Advisor to Dominion Diagnostics.

Monday, February 10, 2014

Dominion Diagnostics launches Kratom testing to address growing designer drug use trend

Dominion Diagnostics, a leading national provider of drug testing, medication monitoring, and clinical support services, launched new testing today that will detect Kratom use. Dominion’s Kratom assay will expand the company’s designer drug testing menu, which already includes detection of synthetic cannabinoids (Spice/K2) and synthetic cathinones (bath salts).

Pages